Company news
GeoVax Labs, Inc. news in 2025
GeoVax Labs, Inc.'s news releases, calls and decks from 2025, newest first.
GeoVax to Raise Approximately $3.2 Million of Gross Proceeds in Public Offering
December 19, 2025
GeoVax Announces Publication of Study Demonstrating Cross-Variant Protection Using the Multi-Antigen GEO-CM04S1 Vaccine
December 18, 2025
GeoVax Receives Formal EMA Scientific Advice Supporting Pivotal Phase 3 Immunobridging Trial for GEO-MVA
December 18, 2025
GeoVax Announces Completion of GEO-MVA Fill-Finish, Supporting Phase 3 Immunobridging Clinical Trial Start-Up in Early 2026
December 17, 2025
GeoVax Receives U.S. Patent Office Notice of Allowance for Broad-Spectrum COVID-19 Vaccine Design
December 16, 2025
GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients
December 15, 2025
GeoVax Addresses Identification of New Mpox Variant
December 11, 2025
GeoVax Announces Addition of Renowned Global Experts to Its Scientific Advisory Board
December 10, 2025
GeoVax Announces Issuance of U.S. Patent Covering Enhanced Therapeutic Use of Gedeptin(R) Gene Therapy
December 9, 2025
GeoVax Announces JCO Oncology Advances Publication Highlighting Favorable Safety and Evidence of Disease Stability of Gedeptin(R) in Recurrent Head & Neck Cancer
December 8, 2025
GeoVax to Present at the Noble Capital Markets Twenty-First Annual Emerging Growth Equity Conference
November 24, 2025
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
November 13, 2025
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
November 10, 2025
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
November 4, 2025
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
November 3, 2025
BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
October 30, 2025
GeoVax Connects IDSA Guidance on COVID-19 Vaccination for Immunocompromised Patients With Recent Clinical Data for GEO-CM04S1
October 29, 2025
GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
October 28, 2025
GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
October 20, 2025
GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
October 16, 2025
GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
October 13, 2025
GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
October 9, 2025
GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
October 7, 2025
GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit
October 1, 2025
GeoVax Labs Announces $2.5 Million Registered Direct Offering
September 30, 2025
GeoVax Comments on U.S. America First Global Health Strategy and Highlights Company's Role in Advancing American Innovation, Pandemic Preparedness, and Global Health Security
September 29, 2025
GeoVax Expands Gedeptin(R) Development to Additional Solid Tumor Indications
September 24, 2025
GeoVax Reaffirms Commitment to Evidence-Based Vaccine Safety and Development of GEO-CM04S1 for Vulnerable Populations
September 22, 2025
GeoVax to Present CM04S1 Clinical Progress at the Emerging Growth Conference
September 18, 2025
GeoVax Showcases Positive Phase 2 Data for GEO-CM04S1 in CLL Patients at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Conference
September 15, 2025
GeoVax Showcases Promising GEO-CM04S1 Clinical Data at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) Conference
September 12, 2025
GeoVax to Present Multi-Antigen COVID-19 Vaccine Clinical Data at September International Scientific Conferences
September 8, 2025
GeoVax to Present at the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
August 20, 2025
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
August 18, 2025
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
August 7, 2025
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
July 30, 2025
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
July 29, 2025
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
July 28, 2025
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
July 28, 2025
GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
July 24, 2025
GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
July 22, 2025
GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
July 21, 2025
GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
July 16, 2025
GeoVax to Present at the Emerging Growth Conference on July 16, 2025
July 14, 2025
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
July 3, 2025
GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
July 2, 2025
GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
July 1, 2025
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
June 25, 2025
GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy
June 24, 2025